osteoprotegerin and Prostatic-Neoplasms--Castration-Resistant

osteoprotegerin has been researched along with Prostatic-Neoplasms--Castration-Resistant* in 1 studies

Other Studies

1 other study(ies) available for osteoprotegerin and Prostatic-Neoplasms--Castration-Resistant

Article	Year
Inhibition of the RANK/RANKL signaling with osteoprotegerin prevents castration-induced acceleration of bone metastasis in castration-insensitive prostate cancer. Cancer letters, 2017, 07-01, Volume: 397 Topics: Androgen Antagonists; Animals; Antineoplastic Agents; Bone Density; Bone Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Orchiectomy; Osteoclasts; Osteoprotegerin; Prostatic Neoplasms, Castration-Resistant; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Recombinant Proteins; Signal Transduction; Tartrate-Resistant Acid Phosphatase; Time Factors; Xenograft Model Antitumor Assays	2017

Article

Year

Inhibition of the RANK/RANKL signaling with osteoprotegerin prevents castration-induced acceleration of bone metastasis in castration-insensitive prostate cancer.

Cancer letters, 2017, 07-01, Volume: 397

Topics: Androgen Antagonists; Animals; Antineoplastic Agents; Bone Density; Bone Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Orchiectomy; Osteoclasts; Osteoprotegerin; Prostatic Neoplasms, Castration-Resistant; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Recombinant Proteins; Signal Transduction; Tartrate-Resistant Acid Phosphatase; Time Factors; Xenograft Model Antitumor Assays

2017